Literature DB >> 24583006

Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates.

Christopher C Fraser1, David H Altreuter1, Petr Ilyinskii1, Lynnelle Pittet1, Robert A LaMothe1, Mark Keegan1, Lloyd Johnston1, Takashi Kei Kishimoto2.   

Abstract

CD4T cells play a key role in humoral immunity by providing help to B cells, enabling effective antibody class switching and affinity maturation. Some vaccines may generate a poor response due to a lack of effective MHC class II epitopes, resulting in ineffective helper T cell activation and recall and consequently poor humoral immunity. It may be beneficial to provide a CD4T cell helper peptide with a vaccine particularly in the case of a poorly immunogenic antigen. Such a T cell helper peptide must be promiscuous in its ability to bind a broad range of MHC class II alleles due to broad allelic variation in the human population. We designed a chimeric MHC class II peptide (TpD) with epitopes from tetanus toxoid and diphtheria toxoid, separated by an internal cathepsin cleavage site. TpD was capable of inducing a memory recall response in peripheral blood mononuclear cells from 20/20 human donors. T cells responding to TpD showed a central memory phenotype. Immunization of mice with a synthetic nicotine nanoparticle vaccine containing TpD showed that the peptide was required for robust antibody production and resulted in a long term CD4 memory T cell recall response. As a pre-clinical model two non-human primate species, rhesus macaques and cynomolgus monkeys, were immunized with a nicotine nanoparticle vaccine and evaluated for an anti-nicotine antibody response and TpD specific memory T cells. We found that 4/4 rhesus monkeys had both sustained antibody production and TpD memory T cells for the duration of the experiment (119 days). In addition 30/30 cynomolgus monkeys dosed with nicotine vaccine nanoparticles showed dose-dependent antibody generation and T cell recall response compared to saline injected controls. In summary we have developed a potent universal memory T cell helper peptide (TpD) that is active in vitro in human PBMCs and in vivo in mice and non-human primates.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; Epitope; Memory T cell; Nanoparticle; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 24583006     DOI: 10.1016/j.vaccine.2014.02.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

Review 1.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

Review 2.  Engineering New Approaches to Cancer Vaccines.

Authors:  Naveen K Mehta; Kelly D Moynihan; Darrell J Irvine
Journal:  Cancer Immunol Res       Date:  2015-07-08       Impact factor: 11.151

3.  Optimization of a multivalent peptide vaccine for nicotine addiction.

Authors:  David F Zeigler; Richard Roque; Christopher H Clegg
Journal:  Vaccine       Date:  2019-02-13       Impact factor: 3.641

Review 4.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

Review 5.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

Review 6.  Nicotine-Targeting Nano-Vaccines for Smoking Cessation.

Authors:  Rajeev I Desai; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2016-01       Impact factor: 7.853

7.  From ZikV genome to vaccine: in silico approach for the epitope-based peptide vaccine against Zika virus envelope glycoprotein.

Authors:  Aftab Alam; Shahnawaz Ali; Shahzaib Ahamad; Md Zubbair Malik; Romana Ishrat
Journal:  Immunology       Date:  2016-09-07       Impact factor: 7.397

8.  Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.

Authors:  Hamilton Kakwere; Elizabeth S Ingham; Riley Allen; Lisa M Mahakian; Sarah M Tam; Hua Zhang; Matthew T Silvestrini; Jamal S Lewis; Katherine W Ferrara
Journal:  Bioconjug Chem       Date:  2017-10-13       Impact factor: 4.774

Review 9.  Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.

Authors:  Mary Speir; Ian F Hermans; Robert Weinkove
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

10.  Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.

Authors:  Rajeev I Desai; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2015-03-06       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.